Acurx Pharmaceuticals Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Dave Luci

Geschäftsführender

US$1.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	46.4%
Amtszeit als Geschäftsführer	6.3yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.9yrs

Jüngste Management Updates

Recent updates

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dave Luci im Vergleich zu den Einnahmen von Acurx Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$475k	-US$15m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$655k	US$475k	-US$12m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	US$4m	US$364k	-US$13m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$596k	US$277k	-US$5m
Dec 31 2019	US$290k	US$267k	-US$6m

Vergütung im Vergleich zum Markt: DaveDie Gesamtvergütung ($USD1.02M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD659.68K).

Entschädigung vs. Einkommen: DaveDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Dave Luci (57 yo)

6.3yrs

Amtszeit

US$1,023,878

Vergütung

Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert DeLuccia	Co-Founder & Executive Chairman	6.3yrs	US$1.06m	6.09% $ 2.3m
David Luci	Co-Founder	6.3yrs	US$1.02m	6.93% $ 2.7m
Joseph Scodari	Independent Director	2.9yrs	US$78.94k	0.019% $ 7.5k
Thomas Harrison	Independent Director	2.9yrs	US$73.94k	0.0097% $ 3.7k
James Donohue	Independent Director	2.9yrs	US$76.44k	0.079% $ 30.4k
Carl Sailer	Independent Director	5.7yrs	US$66.44k	0.74% $ 285.7k
Jack Dean	Independent Director & Scientific Advisor	2.9yrs	US$61.44k	0.11% $ 43.0k
Richard Ellison	Scientific Advisor	no data	keine Daten	keine Daten
Ciaran Kelly	Scientific Advisor	no data	keine Daten	keine Daten
Kevin Garey	Scientific Advisor	no data	keine Daten	keine Daten
Mark Goldberger	Scientific Advisor	no data	keine Daten	keine Daten
Ellie Goldstein	Scientific Advisor	no data	keine Daten	keine Daten

2.9yrs

Durchschnittliche Betriebszugehörigkeit

71yo

Durchschnittliches Alter

Erfahrener Vorstand: ACXPDie Vorstandsmitglieder gelten nicht als erfahren ( 2.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Acurx Pharmaceuticals Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2024

Independent Director exercised options to buy US$75k worth of stock.

Co-Founder exercised options to buy US$77k worth of stock.

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022

Recent updates

Forecast to breakeven in 2026

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2024

Acurx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 15, 2024

Acurx Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering.

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients

Independent Director exercised options to buy US$75k worth of stock.

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Co-Founder exercised options to buy US$77k worth of stock.

Acurx Pharmaceuticals, Inc. Announces Positive Phase 2B Results Showing 100% of Patients Who Has Clinical Cure with Ibezapolstat Also Has Sustained Clinical Cure

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Share price stability

Acurx Pharmaceuticals, Inc. Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

New major risk - Revenue and earnings growth

Acurx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Acurx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acurx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI At the 16Th Biennial Congress of the Anaerobe Society of America

Acurx Pharmaceuticals, Inc. announced a financing transaction

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Acurx Pharmaceuticals, Inc.(NasdaqCM:ACXP) dropped from Russell Microcap Value Index

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022

Acurx Pharmaceuticals, Inc. Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Announces First Patient Enrolled in Phase 2B Clinical Trial of Its Lead Antibiotic for Treatment of Clostridioides Difficile Infection (CDI)

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Acurx Pharmaceuticals, Inc. has completed an IPO in the amount of $15 million.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter